Fair pricing, fair access; a systematic review of cost-effectiveness of new hyperlipidemia injectable medication in developing countries
Cost-effectiveness of PCSK9 inhibitors and inclisiran varies across developing countries, driven by drug prices, WTP thresholds, and healthcare perspectives. Evolocumab may be cost-effective in high-risk subgroups or in Mexico and Saudi Arabia but remains largely unaffordable elsewhere. Ezetimibe was consistently more favorable. Price reductions, tiered pricing, pooled procurement, and context-specific thresholds are essential to improve access and equity.
Authors
- Hamid Pourasghari (ORCID: https://orcid.org/0000-0002-5148-2869)
- Samad Azari (ORCID: https://orcid.org/0000-0003-2781-7793)
- Shahrzad Salehbeigi
- Samira Soleimanpour (ORCID: https://orcid.org/0000-0003-4781-3108)
- Masoud Behzadifar (ORCID: https://orcid.org/0000-0002-0271-4360)
- Masih Tajdini (ORCID: https://orcid.org/0000-0002-5286-9897)
- Dariush Jafarzadeh
- Soheila Rajaei
- Mohammad Ali Rezaei (ORCID: https://orcid.org/0009-0006-6257-8096)
Institutions
- Johns Hopkins University (US)
- Iran University of Medical Sciences (IR)
- Johns Hopkins Medicine (US)
- Lorestan University of Medical Sciences (IR)
- University Hospital Cologne (DE)
Publication Details
- Journal
- Cost Effectiveness and Resource Allocation
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1186/s12962-025-00671-3
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00